Targeted protein degradation Opportunity to partner on co-development or licensing of TPD therapies leveraging SK Life Science Labs’ core platform, E3 ligands, linkers, and MOPED molecular glue capabilities to accelerate preclinical programs in CNS and cancer.

AI driven discovery Sales angle highlighting AI enabled target identification and ternary complex modeling as differentiators, offering faster target validation and potential to de-risk program portfolios for pharma collaborators.

Clinical pipeline signals Recent AACR presentations and preclinical data on p300-selective degraders in aggressive tumors suggest collaboration opportunities around oncology lead optimization, combination strategies, and biomarker driven trials.

Financial potential Company revenue in the lower mid-range with growing activity and a reputable parent company; potential for co-development funding, milestone-based partnerships, and scalable manufacturing support as programs advance.

Strategic connections Proximity to major biotech and cancer research ecosystems through AACR events and industry visibility presents networking avenues with potential collaborators, CROs, and academic partners to expand the R&D footprint.